Trial Profile

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifinatamab deruxtecan (Primary) ; Opevesostat (Primary) ; Abiraterone; Docetaxel; Enzalutamide; Prednisolone
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms IDeate-Prostate02
Sponsors Merck Sharp & Dohme

25 Mar 2026 Planned End Date changed from 24 Feb 2030 to 1 Apr 2031.
25 Mar 2026 Planned primary completion date changed from 18 Feb 2030 to 1 Apr 2031.
26 Jun 2025 Planned End Date changed from 18 Feb 2030 to 24 Feb 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com